AU2016100500A4 - Probiotic compositions for rehydration - Google Patents
Probiotic compositions for rehydration Download PDFInfo
- Publication number
- AU2016100500A4 AU2016100500A4 AU2016100500A AU2016100500A AU2016100500A4 AU 2016100500 A4 AU2016100500 A4 AU 2016100500A4 AU 2016100500 A AU2016100500 A AU 2016100500A AU 2016100500 A AU2016100500 A AU 2016100500A AU 2016100500 A4 AU2016100500 A4 AU 2016100500A4
- Authority
- AU
- Australia
- Prior art keywords
- composition
- mmol
- ions
- lactobacillus
- zinc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 124
- 239000006041 probiotic Substances 0.000 title claims abstract description 21
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 21
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 21
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 230000000813 microbial effect Effects 0.000 claims abstract description 21
- 239000011701 zinc Substances 0.000 claims abstract description 21
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 21
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 18
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 18
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 16
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 16
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 16
- 229910001415 sodium ion Inorganic materials 0.000 claims abstract description 16
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 15
- 239000012141 concentrate Substances 0.000 claims abstract description 15
- 229910001414 potassium ion Inorganic materials 0.000 claims abstract description 15
- 235000000346 sugar Nutrition 0.000 claims abstract description 14
- 239000012736 aqueous medium Substances 0.000 claims abstract description 13
- -1 citrate ions Chemical class 0.000 claims abstract description 13
- 239000000310 rehydration solution Substances 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 35
- 208000005156 Dehydration Diseases 0.000 claims description 23
- 230000018044 dehydration Effects 0.000 claims description 22
- 238000006297 dehydration reaction Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 229960001031 glucose Drugs 0.000 claims description 20
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 18
- 235000001727 glucose Nutrition 0.000 claims description 18
- 229940081969 saccharomyces cerevisiae Drugs 0.000 claims description 17
- 239000001508 potassium citrate Substances 0.000 claims description 13
- 229960002635 potassium citrate Drugs 0.000 claims description 13
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 13
- 235000011082 potassium citrates Nutrition 0.000 claims description 13
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 10
- 229960004106 citric acid Drugs 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 235000002639 sodium chloride Nutrition 0.000 claims description 10
- 239000011670 zinc gluconate Substances 0.000 claims description 10
- 229960000306 zinc gluconate Drugs 0.000 claims description 10
- 235000011478 zinc gluconate Nutrition 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 6
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 229960002668 sodium chloride Drugs 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 abstract description 3
- 235000020299 breve Nutrition 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 239000000835 fiber Substances 0.000 description 12
- 206010010774 Constipation Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 229920000294 Resistant starch Polymers 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000021254 resistant starch Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 229920000189 Arabinogalactan Polymers 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000019312 arabinogalactan Nutrition 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 3
- 201000010538 Lactose Intolerance Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000001904 Arabinogalactan Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000901051 Bifidobacterium animalis subsp. animalis Species 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000178948 Lactococcus sp. Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940035901 lactobacillus sp Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 238000002671 oral rehydration therapy Methods 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Abstract Provided herein are compositions comprising: one or more probiotic microbial strains selected from Saccharomyces cerevisiae, Lactobacilus piantarun, Lactobacillu gasseri and Bifidobaicleriun breve; one or more of potassium ions, sodium ions and/or citrate ions; zinc; and a sugar. Also provided are concentrates for use in preparing an oral rehydration solution, comprising: one or more probiotic microbial strains selected from Saccharonyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve; one or more of potassium ions, sodium ions and/or citrate ions; zinc; and a sugar, wherein the concentrate is mixed with an aqueous medium prior to use to produce a liquid composition for oral administration.
Description
Probiotic compositions for rehydration
Field of the Art [001] The present disclosure relates generally to compositions and methods to provide probiotic supplements useful for the therapeutic and/or prophylactic treatment, amelioration and/or regulation of disease states or pathological conditions. More specifically the present disclosure relates to compositions comprising at least one probiotic microorganism in combination with potassium, sodium and/or citrate ions, zinc and a sugar. The disclosure also relates to uses of such compositions for rehydration and fluid replenishment and for use in the treatment of conditions in which rehydration and fluid replenishment is required, such as diarrhoea and to a lesser extent to decrease the risk of constipation by preventing fluid loss and fluid restriction that may then progress to dehydration or hypohydration.
Background [002] Maintenance of a healthy level of hydration of the human body is essential for the proper functioning of organs and metabolic processes. Electrolyte disturbance and dehydration, the excessive loss of body fluids including water and electrolytes, can compromise a variety of bodily functions and can result from exercise or disease, the latter often associated with poor gastrointestinal health such as diarrhoea and vomiting as well as constipation. Disturbances in water and electrolytes can also occur during attempts to lose weight, in women that are pregnant or breast-feeding, during infections that are accompanied with high fever or when performing work in extreme heat conditions.
[003] To combat dehydration, oral rehydration therapy typically involves the administration of an oral rehydration solution containing glucose and sodium in water. This can provide rapid, effective hydration through sodium ion absorption in the intestines, activated by glucose. Thus, water can be absorbed more rapidly from an ORS containing both sodium and glucose than from water alone. Oral rehydration solutions can be used to treat a variety of conditions including diarrhoea and vomiting and constipation, as well as to maintain a healthy level of hydration.
[004] There is a need for the development of improved compositions and formulations for rehydration and fluid replenishment and to assist in the maintenance of adequate hydration and gastrointestinal health.
Summary of the Disclosure [005] Provided herein are probiotic compositions comprising microbial strains selected from Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus salvarius, Lactococcus lactis, Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium animat is subsp. lactis, Bifidobacterium animalis subsp. animalis, Bifidobacterium infanlis, Bifidobacterium longum, Bifidobacterium pseudocalenulatum, and Saccharomyces cerevisiae.
[006] In a first aspect the present disclosure provides a composition comprising: (i) one or more probiotic microbial strains selected from Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve; (ii) one or more of potassium ions, sodium ions and/or citrate ions; (iii) zinc; and (iv) a sugar.
[007] The composition may comprise two, three or four of said microbial strains. In one embodiment, the composition comprises Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve.
[008] The Saccharomyces cerevisiae may be Saccharomyces cerevisiae spp. boulardii.
[009] In an exemplary embodiment, the potassium ions are provided in the form of potassium citrate.
[0010] In an exemplary embodiment, the sodium ions are provided in the form of sodium chloride.
[0011] In an exemplary embodiment, the citrate ions are provided in the form of citric acid, for example anhydrous citric acid.
[0012] In a particular embodiment, the composition comprises potassium citrate, sodium chloride and citric acid.
[0013] In an exemplary embodiment, the zinc is provided in the form of zinc gluconate.
[0014] The sugar may comprise glucose. The glucose may be anhydrous glucose.
[0015] In one exemplary embodiment, the composition comprises Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri, Bifidobacterium breve, potassium citrate, sodium chloride and citric acid, zinc gluconate and glucose.
[0016] In a second aspect the present disclosure provides a composition consisting essentially of: (i) one or more probiotic microbial strains selected from Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve; (ii) one or more of potassium ions, sodium ions and/or citrate ions; (iii) zinc; and (iv) a sugar.
[0017] In an embodiment, the composition consists essentially of Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri, Bifidobacterium breve, potassium citrate, sodium chloride and citric acid, zinc gluconate and glucose.
[0018] The composition of the first or second aspect may be a rehydration composition for oral administration. In particular embodiments, the composition is mixed with an aqueous medium prior to oral administration. Typically the aqueous medium is water.
[0019] In a third aspect, the present disclosure provides a concentrate for use in preparing an oral rehydration solution or suspension, wherein the concentrate comprises: (i) one or more probiotic microbial strains selected from Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve; (ii) one or more of potassium ions, sodium ions and/or citrate ions; (iii) zinc, and (iv) a sugar, wherein the concentrate is mixed with an aqueous medium prior to use to produce a liquid composition for oral administration.
[0020] The concentrate may comprise or consist, essentially of a composition of the first or second aspect.
[0021] The concentrate may be, for example, in the form of a powder, granules, tablets, capsules or a gel. In a particular embodiment, the concentrate is in dried form, typically a powder. In particular embodiments the aqueous medium is water.
[0022] In a fourth aspect, the present disclosure provides a method for rehydrating a subject, the method comprising administering to the subject a composition of the first aspect or second aspect or an oral rehydration solution or an oral rehydration solution prepared from a concentrate according to the third aspect.
[0023] The subject may be suffering from dehydration due to, for example, excessive sweating, vigorous exercise or a condition associated with dehydration. By way of example, the condition may be cramps, fever, diarrhoea, constipation, vomiting, or other gastrointestinal condition, such as irritable or inflammatory bowel syndrome, coeliac disease or lactose intolerance.
[0024] In a fifth aspect, the present disclosure provides a method for treating one or more symptoms of dehydration in a subject, the method comprising administering to the subject a composition of the first aspect or second aspect or an oral rehydration solution or an oral rehydration solution prepared from a concentrate according to the third aspect.
[0025] In a sixth aspect, the present disclosure provides a method for treating a condition associated with dehydration, or for assisting a subject to recover from a condition associated with dehydration, the method comprising administering to the subject a composition of the first aspect or second aspect or an oral rehydration solution or an oral rehydration solution prepared from a concentrate according to the third aspect.
[0026] In exemplary embodiments, the condition is cramps, fever, diarrhoea, vomiting, constipation or other gastrointestinal condition, such as irritable or inflammatory bowel syndrome, coeliac disease or lactose intolerance.
[0027] Also provided is the use of: one or more probiotic microbial strains selected from
Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and
Bifidobacterium breve/, one or more of potassium ions, sodium ions and/or citrate ions, zinc; and a sugar, in the manufacture of a composition for rehydrating a subject, for treating one or more symptoms of dehydration and/or for treating a condition associated with dehydration, or for assisting a subject to recover from a condition associated with dehydration.
Detaited Description [0028] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, typical methods and materials are described.
[0029] The articles “a” and “an” are used herein to refer to one or to more than one (/'.<?., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0030] In the context of this specification, the term "about," is understood to refer to a range of numbers that a person of skill in the art would consider equivalent to the recited value in the context of achieving the same function or result.
[0031] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises” or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[0032] In the context of this specification, the term “probiotic” is to be given its broadest construction and is understood to refer to a microbial cell population or preparation, or component of a microbial cell population or preparation, which when administered to a subject in an effective amount promotes a health benefit in the subject, [0033] In the context of this specification, the term “prebiotic” is to be given its broadest construction and is understood to refer to any non-digestible substance that stimulates the growth and/or activity of bacteria in the digestive system.
[0034] As used herein, the term “source of fibre” refers to any component or ingredient of a composition that contains, comprises or consists of fibre of dietary' or nutritional benefit to the consumer of the composition. The source of fibre may itself contain or comprise constituents or activities other than fibre, and indeed may be included in the composition other than to provide fibre.
[0035] In the context of this specification, the term "associated with" means a condition, illness or disorder that is caused by, results from or is otherwise characteristic of or associated with dehydration.
[0036] The term "subject" as used herein refers to any mammal, including, but not limited to, livestock and other farm animals (such as cattle, goats, sheep, horses, pigs and chickens), performance animals (such as racehorses), companion animals (such as cats and dogs), laboratory test animals and humans. Typically the subject is a human.
[0037] As used herein, the term "effective amount" refers to an amount of a composition that is sufficient to effect one or more beneficial or desired outcomes. An “effective amount” can be provided in one or more administrations. The exact amount required will vary depending on factors such as the identity and number of individual probiotic strains employed in the composition, the subject being treated, the nature and degree of any disease or condition suffered by the subject and the age and general health of the subject, and the form in which the composition is administered. For any given case, an appropriate “effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.
[0038] As used herein the terms "treating", “treatment” and the like refer to any and all applications which remedy, or otherwise hinder, retard, or reverse the progression of, a condition or at least one symptom of a condition, including reducing the severity of the condition. Thus, treatment does not necessarily imply that a subject is treated until complete elimination of, or recovery from, the condition.
[0039] The term "optionally" is used herein to mean that the subsequently described feature may or may not be present or that the subsequently described event or circumstance may or may not occur. Hence the specification will be understood to include and encompass embodiments in which the feature is present and embodiments in which the feature is not present, and embodiments in which the event or circumstance occurs as well as embodiments in which it does not.
[0040] Provided herein are compositions which find use in improving or assisting maintenance of hydration, an appropriate electrolyte balance, and gastrointestinal health. The compositions of the present disclosure comprise: (i) one or more probiotic microbial strains selected from Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve; (ii) one or more of potassium ions, sodium ions and/or citrate ions, (iii) zinc; and (iv) a sugar.
[0041] The composition may comprise any two or more or three or more of said strains. In an exemplary embodiment, the composition comprises all of said strains.
[0042] The amounts of individual microbial strains included in compositions disclosed herein may depend on a variety of factors including the identity and number of individual strains employed and the form in which the composition is to be administered. By way of example only, the amount of each microbial strain present in a single 5 gram dose of a composition disclosed herein may be from about 1 x 102 cfu to about 1 x 1011 cfu, and may be about 1 x 103 cfu, about 2.5 x 103 cfu, about 5 x 103 cfu, about 7.5 x 103 cfu, 1 x 104 cfu, about 2.5 x 104 cfu, about 5 x 104 cfu, about 7.5x 10'* cfu, about 1 x 105 cfu, about 2.5 x 105 cfu, about 5 x 10’ cfu, about 7.5 x 105 cfu, about 1 x 106 cfu, about 2.5 x 106 cfu, about 5 x 106 cfu, about 7.5 x 10° cfu, about 1 x 10' cfu, about 2.5 x 10 ' cfu, about 5 x 10' cfu, about 7.5 x 10 ' cfu, about 1 x 10s cfu, about 2.5 x 10s cfu, about 5 x 10s cfu, about 7.5 x 10s cfu, about 1 x 109 cfu, about 2.5 x 109 cfu, about 5 x 109 cfu, about 7.5 x 109 cfu, about 1 x 1010 cfu, about 2.5 x 10f 0 cfu, about 5 x 101(j cfu, about 7.5x 1()10 cfu, and about 1 x 1011 cfu.
[0043] In exemplary embodiments, each strain is present in an amount of about 2 x 109 cfu per 5 gram dose of the composition. Thus, in one embodiment, the composition comprises about 2 billion cfu Saccharomyces cerevisiae spp. boidardii, about 2 billion cfu Lactobacillus plantarum, about 2 billion cfu Lactobacillus gasseri and about 2 billion cfu Bifidobacterium, breve per 5 gram dose.
[0044] The composition may further comprise one or more additional probiotic bacterial strains. Suitable additional probiotic bacteria may be selected from Lactobacillus sp,, Lactococcus sp., Streptococcus sp. and Bifidobacterium sp. Exemplary strains include, but are not limited to, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus sal van us, Lactococcus lactis, Streptococcus thermophilus, Bifidobacterium bifidum, Bifidobacterium animalis subsp. lactis (B. lactis), Bifidobacterium animalis subsp. animalis (B. animalis), Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium pseudocatenulatum, [0045] Also contemplated by the present disclosure are variants of the microbial strains described herein. As used herein, the term "variant” refers to both naturally occurring and specifically developed variants or mutants of the microbial strains disclosed and exemplified herein. Variants may or may not have the same identifying biological characteristics of the specific strains exemplified herein, provided they share similar advantageous properties in terms of their ability to be used as probiotic strains. Illustrative examples of suitable methods for preparing variants of the microbial strains exemplified herein include, but are not limited to, culturing under selective growth conditions, gene integration techniques such as those mediated by insertional elements or transposons or by homologous recombination, other recombinant DNA techniques for modifying, inserting, deleting, activating or silencing genes, intraspecific protoplast fusion, mutagenesis by irradiation with ultraviolet light or X-rays, or by treatment with a chemical mutagen such as nitrosoguanidine, methylmethane sulfonate, nitrogen mustard and the like, and bacteriophage-mediated transduction. Suitable and applicable methods are well known in the art and are described, for example, in J. H. Miller,
Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1972); J. H. Miller, A Short Course in Bacterial Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1992), and J. Sambrook, D. Russell, Molecular Cloning: A Laboratory Manual, 3rd ed,, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001), inter alia.
[0046] Also encompassed by the term “variant” as used herein are microbial strains phylogenetically closely related to strains disclosed herein and strains possessing substantial sequence identity with the strains disclosed herein at one or more phylogenetically informative markers such as rRNA genes, elongation and initiation factor genes, RNA polymerase subunit genes, DNA gyrase genes, heat shock protein genes and recA genes. For example, the 16S rRNA genes of a “variant” strain as contemplated herein may share about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with a strain disclosed herein.
[0047] The bacterial strains to be employed in accordance with the present disclosure may be cultured according to any suitable method known to the skilled addressee and may be prepared for addition to a composition by, for example, freeze-drying, spray-drying or lyophilisation. Thus, in embodiments of the present disclosure the bacterial strains may be in a dried form (such as lyophilized or sporulated form) in a suitable earner medium, for example a FOS medium or other soluble fibre, sugar, nutrient or base material for the composition, with which the bacterial strains can be presented in an orally administrable form. One or more of the strains may be encapsulated in, for example, a suitable polymeric matrix to improve long term stability and storage of the compositions. In one example, encapsulation may comprise alginate beads, although those skilled in the art will appreciate that any suitable encapsulation material or matrix may be used. Encapsulation may be achieved using methods and techniques known to those skilled in the art.
[0048] The potassium ions may be provided in any suitable form, for example as potassium citrate, potassium chloride, potassium phosphate, potassium sulphate, or any combination thereof. In a particular embodiment, the potassium ions are provided in the form of potassium citrate.
[0049] The composition may provide potassium ions at a concentration of between about 5 mmol per litre and about 30 mmol per litre of the composition when the composition is in a ready to drink form constituted with an aqueous medium, typically water. The composition may provide potassium ions at a concentration of between about 7 mmol and about 30 mmol, or between about 9 mmol and about 30 mmol, or between about 11 mmol and about 30 mmol, or between about 13 mmol and about 30 mmol, or between about 15 mmol and about 30 mmol, or between about 17 mmol and about 30 mmol, or between about 19 mmol and about 30 mmol, or between about 21 mmol and about 30 mmol, or between about 23 mmol and about 30 mmol, or betv/een about 25 mmol and about 30 mmol per litre. In an exemplary embodiment, the composition provides potassium ions at a concentration of about 22 mmol per litre.
[0050] The composition may comprise potassium citrate at an amount of between about 100 mg and about 1000 mg per 5 gram dose of the composition. For example, the amount of potassium citrate present in a single 5 gram dose of a composition disclosed herein may be about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg or about 1000 mg per 5 gram dose. The composition may comprise potassium citrate at an amount of between about 400 mg and about 500 mg per 5 gram dose, for example about 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg or 500 mg. In an exemplary embodiment the composition comprises about 449 mg potassium citrate per 5 gram dose.
[0051] The sodium ions may be provided in any suitable form, for example as sodium chloride, sodium citrate, sodium phosphate, sodium sulphate, or any combination thereof. In a particular embodiment, the sodium ions are provided in the form of sodium chloride.
[0052] The composition may provide sodium ions at a concentration of between about 20 mmol per litre and about 60 mmol per litre of the composition when the composition is in a ready to drink form constituted with an aqueous medium, typically water. The composition may provide sodium ions at a concentration of between about 20 mmol and about 60 mmol, between about 25 mmol and about 50 mmol, between about 30 mmol and about 50 mmol, between about 35 mmol and about 50 mmol, between about 40 mmol and about 50 mmol, or between about 45 mmol and about 50 mmol per litre. In an exemplary embodiment, the composition provides sodium ions at a concentration of about 46 mmol per litre.
[0053] The composition may comprise sodium chloride at an amount of between about 100 mg and about 1000 mg per 5 gram dose of the composition. For example, the amount of sodium chloride present in a single 5 gram dose of a composition disclosed herein may be about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg or about 1000 mg per 5 gram dose. The composition may comprise sodium chlori de at an amount of between about 500 mg and about 600 mg per 5 gram dose, for example about 500 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560 mg, 570 mg, 580 mg, 590 mg or 600 mg. In an exemplary embodiment the composition comprises about 533 mg sodium chloride per 5 gram dose.
[0054] The citrate ions may be provided in any suitable form, for example as citric acid, sodium citrate, potassium citrate, magnesium citrate, or any combination thereof. In a particular embodiment, the citrate ions are provided in the form of anhydrous citric acid.
[0055] The composition may comprise citric acid at an amount of between about 500 mg and about 1500 mg per 5 gram dose of the compositi on. For example, the amount of citric acid present in a single 5 gram dose of a composition disclosed herein may be about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg or about 1500 mg per 5 gram dose. The composition may comprise citric acid at an amount of between about 800 mg and about 900 mg per 5 gram dose, for example about 800 mg, 810 mg, 820 mg, 830 mg, 840 mg, 850 mg, 860 mg, 870 mg, 880 mg, 890 mg or 900 mg. In an exemplary embodiment the composition comprises about 890 mg citric acid per 5 gram dose.
[0056] The zinc may be present as a zinc salt, such as zinc gluconate. The composition may provide the zinc in a form that provides an amount of zinc equivalent to about 1 mg to about 10 mg per 5 gram dose of the composition. The equivalent zinc amount may be about I mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, or about 10 mg per 5 gram dose. In an exemplary embodiment the composition comprises an equivalent zinc amount of about 6.4 mg per 5 gram dose.
[0057] The composition may provide zinc at a concentration of between about 0.1 mmol per litre and about 2 mmol per litre of the composition when the composition is in a ready to drink form constituted with an aqueous medium, typically water. The composition may provide zinc at a concentration of about 0.1 mmol, 0.2 mmol, 0.3 mmol, 0.4 mmol, 0.5 mmol, 0.6 mmol, 0.7 mmol, 0.8 mmol, 0.9 mmol, 1.0 mmol, 1.1 mmol, 1.2 mmol, 1.3 mmol, 1.4 mmol, 1.5 mmol, 1.6 mmol, 1,7 mmol, 1,8 mmol, 1,9 mmol or 2.0 mmol per litre. In an exemplar}^ embodiment, the composition provides zinc at a concentration of about 0.5 mmol per litre.
[0058] The composition may comprise zinc gluconate at an amount of between about 10 mg and about 100 mg per 5 gram dose of the composition. For example, the amount of zinc gluconate present in a single 5 gram dose of a composition disclosed herein may be about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, or about 100 mg per 5 gram dose. The composition may comprise zinc gluconate at an amount of between about 40 mg and about 50 mg per 5 gram dose, for example about 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg or 50 mg. In an exemplary embodiment the composition comprises about 44.8 mg zinc gluconate per 5 gram dose, [0059] The sugar may be present as a complex or simple sugar. In an exemplary embodiment the sugar is glucose. The glucose may be anhydrous glucose, [0060] The composition may provide glucose at a concentration of between about 50 mmol per litre and about 100 mmol per litre of the composition when the composition is in a ready to drink form constituted with an aqueous medium, typically water. The composition may provide glucose at a concentration of about 50 mmol, about 55 mmol, about 60 mmol, about 65 mmol, about 70 mmol, about 75 mmol, about 80 mmol, about 85 mmol, about 90 mmol, about 95 mmol or about 100 mmol per litre. In an exemplary embodiment, the composition provides glucose at a concentration of about 71 mmol per litre.
[0061] The composition may comprise glucose at an amount of between about 1 g and about 3 g per 5 gram dose of the composition. For example, the amount of glucose present in a single 5 gram dose of a composition disclosed herein may be about 1 g, about 1.5 g, about 2 g, about 2.5 g, or about 3 g per 5 gram dose. The composition may comprise glucose at an amount of between about 2 g mg and about 3 g per 5 gram dose, for example about 2 g, 2,1 g, 2.2 g, 2.3 g, 2.4 g, 2,5 g, 2.6 g, 2.7 g, 2.8 g, 2.9 g or 3 g per 5 g dose. In an exemplary embodiment the composition comprises about 2,5 g glucose per 5 gram dose.
[0062] In some embodiments, compositions of the present disclosure may further comprise one or more prebiotic components, vitamins and/or minerals. Suitable prebiotics include polydextrose, inulin, fructooligosaccharides (FOS), xylooligosaccharides (XOS), galactooligosaccharides (GOS), mannan oligosaccharides, protein-based green lipped mussel extract, and various prebiotic-containing foods such as raw onion, raw leek, raw chickory root and raw artichoke. The vitamins and minerals may be selected from, but not limited to: vitamins A, Bi, B2, B;, B5, B6, B9, Bi2, C, D, E and calcium, chromium, copper, fluorine, iodine, iron, magnesium, manganese, molybdenum, phosphorus, and selenium.
[0063] Compositions of the present disclosure may further comprise one or more amino acids. The amino acids may be selected from, but are not limited to: alanine, arginine, aspartic acid, cystine, glycine, histidine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan and tyrosine.
[0064] Compositions of the present disclosure may further comprise one or more antioxidants or sources of antioxidant activity. Exemplar}' antioxidants may be water soluble or lipid soluble and include, but are not limited to, carotenes (e.g, beta-carotene, lycopene, lutein, zeaxanthin), flavonoids, tocopherols, tocotrienols, polyphenols (e.g. resveratrol, catechins), glutathione, anthocyanins, vitamins (e.g. vitamin A, vitamin C, vitamin E) and their derivatives, coenzymes (e.g. coenzyme Q10), and minerals (e.g. selenium, copper, zinc, manganese). Suitable sources of antioxidant activity include various plant extracts, herbal extracts and spices, as will be readily appreciated by those skilled in the art.
[0065] Compositions of the present disclosure may further comprise a source of fibre. The source of fibre may comprise soluble fibre, insoluble fibre, or a combination of both soluble and insoluble fibre. Suitable sources of soluble fibre include, but are not limited to, psyllium, dextrins, fructans, oligosaccharides (e.g. inulins) and polysaccharides. Exemplary polysaccharides include arabinogalactans and resistant starches. Arabinogalactans are complex proteoglycans of arabinose and galactose, often classified as plant or microbial arabinogalactan. An exemplar}'· arabinogalactan is Larch arabinogalactan. The resistant starch may be an RSI, RS2„ RS3 or RS4 resistant starch. An exemplary' resistant starch is Hi-Maize resistant starch.
[0066] The compositions may additionally include any suitable additives, carriers, additional therapeutic agents, bioavailability enhancers, side-effect suppressing components, diluents, buffers, flavouring agents, colouring agents, binders, preservatives or other ingredients that are not detrimental to the efficacy of the composition.
[0067] In particular embodiments, the composition may be gluten free and dairy free, and suitable for ingestion by vegetarians.
[0068] Compositions of the invention can be readily manufactured by those skilled in the art using known techniques and processes. For example, the microbial strains can be seeded from standard stock into a reactor and grown in standardized media until a predetermined cfu/g concentration is reached. The bulk material can then be drained from the reactor and dried by spray drying, lyophilization, or flatbed oven drying. The dried bacterial material can then be blended with the carrier medium and the resulting mixture can be pressed into tablets, filled into foil pouches as a granular solid, or introduced into gelatin capsules as a particulate material.
[0069] Compositions of the present disclosure may be suitably formulated for oral administration, and may be prepared according to conventional methods well known in the pharmaceutical and nutraceutical industries, such as those described in Remington’s Pharmaceutical Handbook (Mack Publishing Co., NY, USA) using suitable excipients, diluents and fillers.
[0070] Compositions may be dried to form, for example, a powder, granules, capsules or tablets. For oral administration, the composition may then be mixed with a suitable volume of an aqueous medium, typically with agitation, to dissolve the components, or produce a suspension, suitable for ingestion. Thus, the compositions may be provided to a user in a powder form, which powder may then be added by the user to any type of aqueous medium (for example water or fruit juice) and consumed there after. Alternatively, the composition may be provided as a beverage, pre-mixed with an aqueous medium such as water.
[0071] By way of example, a 5 gram dose of a composition of the present disclosure may be added to 200 ml water and stirred immediately prior to administration to a subject.
[0072] Also provided herein are methods for rehydrating a subject, and for treating one or more symptoms of dehydration, comprising administering to a subject in need thereof a composition of the present disclosure. The subject may be suffering from dehydration due to, for example, excessive sweating, vigorous exercise or a condition associated with dehydration. Typical symptoms associated with dehydration include, but are not limited to: headache, decreased blood pressure, thirst, faintness, dizziness, fatigue, appetite loss, constipation, darkened urine, and dry mouth.
[0073] Also provided are methods for treating conditions associated with dehydration, or for assisting in the recovery from conditions associated with dehydration, comprising administering to a subject in need thereof a composition of the present disclosure. A number of conditions such as fever, cramps, diarrhoea, vomiting, constipation and other gastrointestinal conditions (such as irritable or inflammatory bowel syndrome, coeiiac disease or lactose intolerance) may lead to mild to severe dehydration, or be otherwise associated with dehydration. Thus, compositions of the present disclosure may be consumed by individuals suffering from such conditions in order to re-establish electrolyte balance and replace lost fluid, [0074] Compositions of the present disclosure may also be consumed before, during and/or after exercise, or other form of physical exertion, which may lead to a depletion in the amount of fluid and electrolytes in the body.
[0075] For the various circumstances in which a composition of the present disclosure may be administered, those skilled in the art will appreciate that the amount of the consumed, and the number of discreet consumptions per unit time will vary depending on the actual use to which the composition is put, the condition of the subject who will consume the beverage, the subject's age, sex, weight and general health. By way of example, a 5 gram dose of a composition of the present disclosure may be added to 200 ml water and stirred immediately prior to administration. Typically, several divided doses may be administered in half hourly or hourly, daily or at other suitable time intervals, and/or the dose may be proportionally reduced or increased as indicated by the exigencies of the situation.
[0076] By way of example only, a suitable dose of a beverage prepared by the addition of 5 grams of composition to 200 mi of water may be 200 ml every' 30 mins (as required) for adults and for children over 12 years of age, 100 ml every' 30 mins (as required) for children between 6 to 12 years of age, 100 ml every 60 mins (as required) for children between 3 to 6 years of age, or 100 ml every 90 mins (as required) for children under 3 years of age. Those skilled in the art. will appreciate that the amount of composition to be reconstituted in water, the amount of water, the amount of beverage to be consumed and the frequency of consumption may be varied according to requirements of the individual subject. Suitable dosages, frequency of administration of doses and length of time that administration is continued may be determined in consultation with a healthcare practitioner.
[0077] The reference in this specification to any prior publication (or information derived from it), or to any matter winch is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
[0078] The present disclosure will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the invention.
Examples [0079] The following examples are illustrative of the invention and should not be construed as limiting in any way the general nature of the disclosure of the description throughout this specification.
Example 1 - Oral powder composition [0080] An exemplary probiotic composition according to the present disclosure has the following ingredients, per 5 gram dose:
Probiotic components:
Lactobacillus plantarum 2 billion cfu
Lactobacillus gasseri 2 billion cfu
Bifidobacterium breve 2 billion cfu
Saccharomyces cere visiae spp. boulardii 2 billion cfu
Other active components: S odium ch l ori de 533.2 mg
Equiv. sodium 209.7 mg (46 mmol/L in 200 ml water)
Equiv. chloride 323.5 mg (46 mmol/L in 200 mi water)
Potassium citrate 449.1 mg
Equiv. potassium 162.6 mg (22 mmol/L in 200 mi water)
Equiv. citrate 261.8 mg (30 mmol/L in 200 ml water)
Citric acid (anhydrous) 890.5 mg
Glucose (anhydrous) 2.5 g (71 mmol/L in 200 ml water)
Zinc gluconate 44.8 mg (1 mmol/L in 200 ml w7ater)
Equiv. zinc 6.4 mg (0.5 mmol/L in 200 ml water)
Other ingredients:
Natural orange flavour Silica
Steviol glycosides Natural colour
Gluten free Dairy free
Product may be formulated as a powder (typically 5 g dissolved in 200 mL water or other liquid) to be taken evety 30 min, 60 min or 90 min, as required.
Claims (5)
- Claims1. A composition comprising: (i) one or more probiotic microbial strains selected from Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve; (ii) one or more of potassium ions, sodium ions and/or citrate ions; (iii) zinc; and (iv) a sugar.
- 2. A composition according to claim 1 or 2, wherein the composition comprises Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve. a
- 3. A composition comprising Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri, Bifidobacterium breve, potassium citrate, sodium chloride and citric acid, zinc gluconate and glucose.
- 4. A concentrate for use in preparing an oral rehydration solution, wherein the concentrate comprises: (i) one or more probiotic microbial strains selected from Saccharomyces cerevisiae, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium breve; (ii) one or more of potassium ions, sodium ions and/or citrate ions; (iii) zinc; and (iv) a sugar, wherein the concentrate is mixed with an aqueous medium prior to use to produce a liquid composition for oral administration.
- 5. A method for rehydrating a subject, for treating condition associated with dehydration one or more symptoms of dehydration, the method comprising administering to the subject a composition according to any one of claims 1 to 3 or an oral rehydration solution prepared from a concentrate according to claim 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016100500A AU2016100500A4 (en) | 2015-05-01 | 2016-05-02 | Probiotic compositions for rehydration |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015901570A AU2015901570A0 (en) | 2015-05-01 | Probiotic compositions for rehydration | |
AU2015901570 | 2015-05-01 | ||
AU2016100500A AU2016100500A4 (en) | 2015-05-01 | 2016-05-02 | Probiotic compositions for rehydration |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2016100500A4 true AU2016100500A4 (en) | 2016-06-02 |
Family
ID=56080576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016100500A Expired AU2016100500A4 (en) | 2015-05-01 | 2016-05-02 | Probiotic compositions for rehydration |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2016100500A4 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115210360A (en) * | 2021-02-09 | 2022-10-18 | 乐土美森有限公司 | Novel lactobacillus reuteri LM1071 strain derived from breast milk, and composition for alleviating premenstrual syndrome comprising the same or culture thereof |
-
2016
- 2016-05-02 AU AU2016100500A patent/AU2016100500A4/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115210360A (en) * | 2021-02-09 | 2022-10-18 | 乐土美森有限公司 | Novel lactobacillus reuteri LM1071 strain derived from breast milk, and composition for alleviating premenstrual syndrome comprising the same or culture thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6651450B2 (en) | Use of a composition comprising a microorganism for increasing intestinal production of butyric acid, folic acid, or niacin and / or for reducing intestinal production of succinic acid | |
ES2929100T3 (en) | Treatment for depression and depressive disorders | |
RU2543815C2 (en) | Nutritional compositions containing lactoferrin and probiotics and sets of their parts | |
AU2015202755B2 (en) | Probiotic combinations and uses thereof | |
AU2015100952A4 (en) | Probiotic- and enzyme-containing compositions and uses thereof | |
CN105142654B (en) | Lachnospiraceae in the gut microbiota and correlation with body weight | |
EP1947962B1 (en) | Edible product containing ginseng polysaccharides and beneficial bacteria | |
Divya et al. | Encapsulated Lactococcus lactis with enhanced gastrointestinal survival for the development of folate enriched functional foods | |
JP7219801B2 (en) | Compositions and methods for preventing and/or treating vitamin B12 deficiency | |
CN103689595A (en) | Soft lactic acid bacteria capsule and preparation method thereof | |
ES2760256T3 (en) | Composition | |
US20200345795A1 (en) | Modulation of intestinal microbiota in pre-diabetes and type 2 diabetes | |
AU2015100928A4 (en) | Probiotic combinations and uses thereof | |
Maurya et al. | Probiotics: an approach towards health and disease | |
Vijaya Kumar et al. | Beneficial effects of probiotics and prebiotics on human health | |
AU2016100500A4 (en) | Probiotic compositions for rehydration | |
AU2016100499A4 (en) | Yeast-containing compositions for gastrointestinal health | |
AU2016100501A4 (en) | Probiotic compositions for weight management | |
US20220192246A1 (en) | Composition and method for synbiotics supplement containing probiotics, digestive enzymes, prebiotics, yeast, protein, b vitamins, and flavoring agent | |
US20220047659A1 (en) | Symbiotic supplement formulation for improving intestinal microbiota | |
US20200281993A1 (en) | Diagnostic and therapeutic methods for type 2 diabetes | |
KR102534536B1 (en) | Composition and manufacturing method effective for antibacterial, antioxidant, and immunity enhancement using Probiotics Lactobacillus and red ginseng in the intestine of companion animal | |
Combrinck et al. | Probiotics and Prebiotics | |
Patil et al. | Improving the Gut Microbiota with Probiotics and Faecal Microbiota Transplantation. | |
Combrinck et al. | Probiotics and prebiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
PC | Assignment registered |
Owner name: PHARM-A-CARE LABORATORIES PTY LTD Free format text: FORMER OWNER(S): MEDLAB IP PTY LTD |
|
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |